LegalOct 8, 2026, 08:06 AM
Quantum BioPharma Lawsuit Against Banks Consolidated; Lead Counsel Appointed
AI Summary
Quantum BioPharma Ltd. announced that the United States District Court for the Southern District of New York has consolidated its direct action and a class action lawsuit against Canadian banks CIBC and RBC. The lawsuits allege illegal stock market manipulation of Quantum BioPharma shares. The court has appointed Grant & Eisenhofer P.A. as lead counsel in the class action. The class action lawsuit, filed in December 2025, alleges shareholders were harmed between January 2021 and October 2025.
Key Highlights
- Quantum BioPharma announces consolidation of its direct action and a class action lawsuit against Canadian banks CIBC and RBC.
- The lawsuits allege illegal stock market manipulation of Quantum BioPharma shares between January 2020 and October 2025.
- Grant & Eisenhofer P.A. appointed as lead counsel in the consolidated class action lawsuit.
- The company formerly known as FSD Pharma Inc. is also mentioned in relation to the class action.
Price Impact
More from QNTM